文献速递青光眼

评估晚期青光眼患者的初始治疗:晚期青光眼治疗研究的五年结果

Evaluating Primary Treatment for People with Advanced Glaucoma: Five-Year Results of the Treatment of Advanced Glaucoma Study.
PubMed 文献 · Ophthalmology · 2024-01-09

这项多中心随机对照试验纳入453例新诊断的晚期开角型青光眼成人患者,比较初始小梁切除术与药物治疗的5年结局。5年时两组视功能问卷(VFQ-25)评分无显著差异,但小梁切除术组眼压更低、视野平均偏差更好,安全性事件无显著差异。

要点

  • 5年时小梁切除术组与药物组VFQ-25评分差异无统计学意义(P=0.51)。
  • 小梁切除术组平均眼压较药物组低2.56 mmHg(P<0.001)。
  • 小梁切除术组视野平均偏差较药物组好1.87 dB(P<0.001)。

核心结论

  • 5年时,晚期青光眼治疗研究表明,对于晚期患者,初始小梁切除术在降低眼压和防止疾病进展方面比初始药物治疗更有效,且安全性相似。

研究设计与样本

  • 多中心随机对照试验,2014年6月3日至2017年5月31日从英国27个二级护理青光眼科室招募453例新诊断的晚期开角型青光眼成人患者(至少1眼符合Hodapp分类),227例分配至小梁切除术组,226例分配至药物管理组。
  • 参与者按1:1随机接受丝裂霉素C增强的小梁切除术或使用降眼压滴眼液的递增药物管理作为初始干预,随访5年。

主要发现

  • 5年时,小梁切除术组和药物组的平均±标准差VFQ-25评分分别为83.3±15.5和81.3±17.5,平均差异为1.01(95%CI,-1.99至4.00;P=0.51)。
  • 小梁切除术组和药物组的平均眼压分别为12.07±5.18 mmHg和14.76±4.14 mmHg,平均差异为-2.56(95%CI,-3.80至-1.32;P<0.001)。
  • 小梁切除术组和药物组的视野平均偏差分别为-14.30±7.14 dB和-16.74±6.78 dB,平均差异为1.87(95%CI,0.87-2.87 dB;P<0.001)。
  • 小梁切除术组115例(52.2%)和药物组124例(57.9%)发生安全性事件(相对风险,0.92;95%CI,0.72-1.19;P=0.54)。
  • 严重不良事件罕见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether primary trabeculectomy or medical treatment produces better outcomes in terms of quality of life (QoL), clinical effectiveness, and safety in patients with advanced glaucoma. DESIGN: Multicenter randomized controlled trial. PARTICIPANTS: Between June 3, 2014, and May 31, 2017, 453 adults with newly diagnosed advanced open-angle glaucoma in at least 1 eye (Hodapp classification) were recruited from 27 secondary care glaucoma departments in the United Kingdom. Two hundred twenty-seven were allocated to trabeculectomy, and 226 were allocated medical management. METHODS: Participants were randomized on a 1:1 basis to have either mitomycin C-augmented trabeculectomy or escalating medical management with intraocular pressure (IOP)-reducing drops as the primary intervention and were followed up for 5 years. MAIN OUTCOME MEASURES: The primary outcome was vision-specific QoL measured with the 25-item Visual Function Questionnaire (VFQ-25) at 5 years. Secondary outcomes were general health status, glaucoma-related QoL, clinical effectiveness (IOP, visual field, and visual acuity), and safety. RESULTS: At 5 years, the mean ± standard deviation VFQ-25 scores in the trabeculectomy and medication arms were 83.3 ± 15.5 and 81.3 ± 17.5, respectively, and the mean difference was 1.01 (95% confidence interval [CI], -1.99 to 4.00; P = 0.51). The mean IOPs were 12.07 ± 5.18 mmHg and 14.76 ± 4.14 mmHg, respectively, and the mean difference was -2.56 (95% CI, -3.80 to -1.32; P < 0.001). Glaucoma severity measured with visual field mean deviation were -14.30 ± 7.14 dB and -16.74 ± 6.78 dB, respectively, with a mean difference of 1.87 (95% CI, 0.87-2.87 dB; P < 0.001). Safety events occurred in 115 (52.2%) of patients in the trabeculectomy arm and 124 (57.9%) of patients in the medication arm (relative risk, 0.92; 95% CI, 0.72-1.19; P = 0.54). Serious adverse events were rare. CONCLUSIONS: At 5 years, the Treatment of Advanced Glaucoma Study demonstrated that primary trabeculectomy surgery is more effective in lowering IOP and preventing disease progression than primary medical treatment in patients with advanced disease and has a similar safety profile. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. King AJ, Hudson J, Azuara-Blanco A, et al. Evaluating Primary Treatment for People with Advanced Glaucoma: Five-Year Results of the Treatment of Advanced Glaucoma Study. Ophthalmology. 2024. PMID: 38199528. doi:10.1016/j.ophtha.2024.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。